P5065 - GLP-1 RA Use in Patients with T2DM is Associated with Lower Risk of Gastric Cancer: A National Analysis

Mark Ayoub, MD¹, Carol Faris, MD², Tiana Dodd, DO³, Rafi Aibani, MD⁴, Nisar Amin, MD¹, Ebubekir Daglilar, MD¹, Roberta Hunter, MD^1
1West Virginia University - Charleston Area Medical Center, Charleston, WV; ²CarePoint Health - Bayonne Medical Center, Charleston, WV; ³Charleston Area Medical Center, Charleston, WV; ⁴CAMC, Charleston, WV

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RA), such as exenatide, liraglutide, and semaglutide, are becoming more popular in managing type 2 diabetes mellitus (T2DM), especially for their cardiovascular, renal, and metabolic benefits. Despite this, concerns linger over their potential link to malignant neoplasms like pancreatic and thyroid cancers, requiring more research to clarify their safety profiles. Additionally, evidence suggests GLP-1RAs may lower colorectal and pancreatic cancer risk, especially in obese or overweight individuals, indicating a protective effect beyond weight loss. Current studies leave a gap in comprehensively understanding cancer risks associated with GLP-1RA which prompts further research to enhance our understanding of their overall safety.

Methods: We queried the US Collaborative Network (63 healthcare organizations) of TriNetX research database. Patients with T2DM were identified and divided into two cohorts; patients on GLP-1 RAs, and patients not on GLP-1 RAs. We excluded obese patients with body mass index (BMI) >25 kg/m2, family history of gastrointestinal malignancy, infectious mononucleosis, chronic gastritis, pernicious anemia, helicobacter pylori infection, and gastroesophageal reflux disease (GERD). We used a 1:1 propensity-score matching (PSM) model using patient’s baseline characteristics, medications, and genetics. A full list of PSM components is highlighted in table 1. We compared the rate of gastric cancer and esophageal cancer at the 7-year mark.

Results: A total of 3,851,241 patients with T2DM were identified. Of those, 7.7% (n=294,781) were on a GLP-1 RA and 92.3% (3,556,462) were not on a GLP-1 RA. After PSM, both cohorts included 294,779 patients. Patients with T2DM who were on a GLP-1 RA compared to those who are not had a statistically significant lower risk of both gastric cancer (0.04% vs 0.13%, p< 0.0001) at the 7-year mark. Gastric cancer risk difference with GLP-1 RA use was -0.08% with a 95% CI (-0.1, -0.07).

Discussion: The use of GLP-1 RA in patients with T2DM is significantly associated with the lower risk of having gastric cancer. This finding supports the continued use of GLP-1 analogues as a therapeutic option in managing T2DM, considering their well-established benefits and low risk of complications. Based on the study results, these medications may even have a protective effect.


Disclosures:


Mark Ayoub, MD¹, Carol Faris, MD², Tiana Dodd, DO³, Rafi Aibani, MD⁴, Nisar Amin, MD¹, Ebubekir Daglilar, MD¹, Roberta Hunter, MD¹. P5065 - GLP-1 RA Use in Patients with T2DM is Associated with Lower Risk of Gastric Cancer: A National Analysis, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.